Restoration of functionality in postpartum depressed mothers: An open-label study with escitalopram

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 729-732

  Misri, Shaila ^a,b   Abizadeh, Jasmin ^a,b   Albert, Gillian ^a,b   Carter, Diana ^a,b   Ryan, Deirdre ^a,b  

^a BC Children's and Women's Hospital   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM;

ANXIETY DISORDER; BREAST FEEDING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; HEADACHE; HUMAN; LETTER; MOOD DISORDER; NAUSEA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PUERPERAL DEPRESSION; QUALITY OF LIFE; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; XEROSTOMIA;

ADULT; CITALOPRAM; DEPRESSION, POSTPARTUM; FEMALE; HUMANS; PREGNANCY; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECOVERY OF FUNCTION; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865864652     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31826867c9     Document Type: Letter

References (17)

1. O'Hara MW, Swain AM. Rates and risk of postpartum depressionVa meta-analysis. Int Rev Psychiatry. 1996;8:37-54.
2. Altshuler LL, Hendrick V, Cohen LS. Course of mood and anxiety disorders during pregnancy and the postpartum period. J Clin Psychiatry. 1998;59(suppl 2):29-33.
3. Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety. 1997;4:160-168.
4. Lanza di Scalea T, Wisner KL. Pharmacotherapy of postpartum depression. Expert Opin Pharmacotherapy. 2009; 10:2593-2607.
5. Misri S, Reebye P, Corral M, et al. The use of paroxetine and cognitive behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. J Clin Psychiatry. 2004;65:1236-1241.
6. O'Hara MW, Stuart S, Gorman LL, et al. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry. 2000;57:1039-1045.
7. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
8. Rabinowitz I, Baruch Y, Barak Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2008;23:49-53.
9. Pelissolo A. Efficacy and tolerability of escitalopram in anxiety disorders: a review. Encephale. 2008;34:400-408.
10. Cassin SE, Richter MA, Zhang AK, et al. Quality of life in treatment-seeking patients with obsessive-compulsive disorder with and without major depressive disorder. Can J Psychiatry. 2009; 54:460-467.
11. Bosquet M, Egeland B. Associations among maternal depressive symptomatology, state of mind and parent and child behaviors: implications for attachment-based interventions. Attach Hum Dev. 2001; 3:173-199.
12. Beck CT. The effects of postpartum depression on maternal infant interaction: a meta-analysis. Nurs Res. 1995;44:298-304.
13. Beck CT. The effects of postpartum depression in child development: a meta-analysis. Arch Psychiatric Nurs. 1998;12:12-20.
14. Rampono J, Hackett LP, Kristensen J H, et al. Transfer of escitalopram and its metabolite demethylescitalopram into breast milk. Br J Clin Psychiatry. 2006;62:316-322.
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
16. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
17. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacology Bull. 1993;29: 321-326.